ReviewInternational journal of nanomedicine2026
Graphene and Graphene Oxide-Based Nanocarriers for Targeted Delivery of Mitoxantrone in Cancer Therapy.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mitoxantrone (MTX) is limited by cardiotoxicity and MDR. At the same time, graphene oxide (GO) and nano-graphene oxide (NGO) offer ultrahigh surface area, strong π-π interactions with aromatic drugs, and versatile surface chemistry, making them superior to many conventional nanocarriers for high-capacity, stimuli-responsive MTX delivery. Conventional chemotherapy remains constrained by nonspecific biodistribution, dose-limiting toxicity, and the frequent emergence of multidrug resistance. This review surveys recent advances in GO- and NGO-based nanocarriers developed for targeted delivery of mitoxantrone. The platforms examined include hyaluronic acid-Pluronic functionalization for CD44-mediated targeting and P-glycoprotein inhibition, biomimetic coatings derived from mesenchymal stem cells or cancer-cell exosomes, magnetic graphene oxide systems designed for mitochondrial delivery, hybrid gold-graphene constructs, and multi-stimuli-responsive designs that respond to acidic pH, near-infrared light, or external magnetic fields. Combination strategies that integrate chemotherapy with photothermal therapy, nitric oxide release, or immunotherapy are also considered. Molecular dynamics simulations together with in vitro and limited in vivo studies indicate high drug-loading capacities (commonly reaching 40-45 wt% and higher in selected systems), stimulus-triggered release within acidic microenvironments, improved intracellular accumulation in resistant cell lines, and enhanced antitumor activity relative to free MTX in preclinical models, frequently accompanied by reduced systemic exposure. Nevertheless, long-term biocompatibility, immunogenicity, biodegradation and clearance pathways, batch-to-batch reproducibility, scalable manufacturing, and the complete absence of clinical data remain major translational barriers. Further progress will require safer, more biodegradable graphene derivatives and rigorous toxicological characterization before these platforms can advance toward clinical evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.